Clinical trials: Histological Response
Melanoma
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
This study uses molecular imaging and novel immune monitoring to identify a biomarker of response for melanoma patients receiving immunotherapy with anti-PD-1 immunotherapy.
- Trial name
- NCT03356470
- Testing
- F-FDG PET/CT
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Wisconsin, Madison
Mantle Cell Lymphoma (MCL)
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL) is a form of Non-Hodgkin Lymphoma (NHL - cancer of the lymphatic system in blood) where cells from outer edge of the lymph nodes, called mantle zone become cancerous.
- Trial name
- NCT04477486
- Testing
- Ibrutinib, Venetoclax
- Where
- 12 sites in Japan
- Volunteers
- 13 people
- Sponsor
- AbbVie
BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites…
- Conditions
- BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05250895
- Testing
- 18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Myxoid Liposarcoma
Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial)
After a screening, which consists of pathology confirmation, physical examination, magnetic resonance imaging (MRI), body computed tomography (CT) scan, blood tests, and case analysis on Multidisciplinary Team (MDT) meeting…
- Trial name
- LIPOMYX (NCT03816475)
- Testing
- Hypofractionated radiotherapy
- Where
- Poland
- Volunteers
- 35 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Diffuse Large B-cell Lymphoma
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial remission after 6 cycles of CHOP therapy.
- Trial name
- NCT00440583
- Testing
- chemotherapy followed by Zevalin
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Mahidol University
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have relapsed after achieving a complete response in…
- Trial name
- NCT01226472
- Testing
- KW-0761
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Leukemia
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- CML0206 (NCT00466726)
- Testing
- bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, sargramostim
- Where
- 17 sites in Italy
- Volunteers
- 57 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Peripheral T Cell Lymphoma
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
This is a multicenter, randomized, double-blind, phase III clinical study comprising two arms: a golidocitinib group and a placebo group.
- Trial name
- T-START-M1 (NCT07414758)
- Testing
- golidocitinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
HCC - Hepatocellular Carcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
This study is a multicenter retrospective clinical research, led by the First Affiliated Hospital of Wenzhou Medical University, and jointly conducted by other sub-centers.
- Trial name
- NCT07495735
- Testing
- No intervention (observational study)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Oesophageal Adenocarcinoma, Tumor Microenvironment
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
- Trial name
- MEMENTO (NCT06687876)
- Testing
- Metformin
- Where
- 2 sites in Netherlands
- Volunteers
- 14 people
- Sponsor
- Amsterdam UMC, location VUmc
Sarcoma
PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
Purpose: To assess the utility of PET/MR in assessing response to neoadjuvant radiation therapy in the treatment of high grade sarcomas.
- Trial name
- NCT03076333
- Testing
- PET/MR
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML)
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
This is a Phase I/II trial to determine safety, clinical efficacy and feasibility of a gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
- Trial name
- NCT02550535
- Testing
- Autologous WT1 TCR transduced T cells
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 3 people
- Sponsor
- Cell Medica Ltd
Chronic Myeloid Leukemia
Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response
Multi-Center, national, non-drug, prospective cohort study Target patient number is 100 The amount of CD45+/CD34+/CD38-/CD26+ levels of chronic myeloid leukemia (CML) stem cells in CML patients with and without BCR-ABL…
- Trial name
- NCT04104035
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Ankara University
Melanoma Stage III, Melanoma Stage IV
FMT to Convert Response to Immunotherapy
In this study the aim is to investigate whether transfer of the microbiota of either responder or non-responder patients via fecal microbiotica transplantation (FMT) can convert the response to immunotherapy in immune checkpoint…
- Trial name
- NCT05251389
- Testing
- Fecal microbiota transplantation
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- The Netherlands Cancer Institute
Gastrointestinal Stromal Tumors
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
The aim of this study is to demonstrate that the use of Gleevec in initially non-resectable gastrointestinal stromal tumors can lead to allow complete resection in 20% of cases.
- Trial name
- NCT00290485
- Testing
- Imatinib mesylate
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Melanoma
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
Despite being standard of care, there are still many medical requirements related to immune checkpoint blocker based therapies such as identify patients susceptible to respond with the less adverse events, evaluate the clinical…
- Trial name
- PHENOMENAL (NCT06154668)
- Where
- France
- Volunteers
- 707 people
- Sponsor
- University Hospital, Grenoble
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Melanoma Metastatic, Melanoma, Skin
Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
The goal of this observational study is to assess whether the IOpener® melanoma test can assist treating physicians in deciding which therapy is most suitable for patients with skin cancer (advanced cutaneous melanoma).
- Conditions
- Melanoma Metastatic, Melanoma, Skin, Melanoma Stage III or IV, Melanoma Advanced
- Trial name
- COMO (NCT06784778)
- Testing
- PBMC Kinase Activity Profile
- Where
- 3 sites in Germany
- Volunteers
- 196 people
- Sponsor
- Pamgene International B.V.
Head and Neck Cancer
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Primary Compare response rates (relative change in tumor size) to induction chemotherapy consisting of cisplatin/paclitaxel/cetuximab +/- everolimus.
- Trial name
- NCT01133678
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Soft Tissue Sarcoma (STS)
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma
This study is a multicenter, prospective, randomized controlled phase II clinical trial designed to evaluate the efficacy and safety of Spatially Fractionated Radiation Therapy (SFRT) compared to Conventional Radiation Therapy…
- Trial name
- NCT06980259
- Testing
- Spatially Fractionated Radiotherapy, Conventional Radiotherapy
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Shandong Cancer Hospital and Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.